Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview and Market Definition
- Macroeconomic Factors
- Porter's Five Forces Model
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Potential for New Entrants
- Competition in the Industry
- Threat of Substitutes
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Prevalence of Genetic Disorders
- New Genome-Editing Technologies and Applications
- Increasing Government and Private Funding
- Market Restraints
- Governmental Policies and Regulations
- Ethical and Societal Concerns
- Market Opportunities
- Expanding Applications for CRISPR Technology
- Applications in Plant and Livestock Breeding
- Market Challenges
- Scalability Constraints in Gene Editing Workflows
- Cost of CRISPR-based Therapy
Chapter 4 Regulatory Landscape
- Regulatory Scenario, by Country/Region
- North America
- EU
- Asia-Pacific
- Rest of the World
Chapter 5 Emerging Technologies and Developments
- Emerging Technologies
- In Vivo Delivery of CRISPR
- Improved Cas Variants
- Artificial Intelligence
- Takeaways: Emerging Technologies in CRISPR
- Clinical Trials Analysis
- Clinical Trials Analysis, by Type of Study
- Clinical Trials Analysis, by Status
- Clinical Trials Analysis, by Phase
- Selected Clinical Trials
- Takeaways: Clinical Trials Landscape
- Patent Analysis
- Patents, by Year
- Patents, by Leading Applicant
- Patents, by Leading Patent Holder
- Recent Patents Relating to Genome Editing Technology
- IP Disputes and Patent Issues
- Key Takeaways: Patent Landscape (2020-2024)
Chapter 6 Market Segment Analysis
- Segmentation Breakdown
- Global Genome Editing Market, by Technology Type
- CRISPR-Cas
- TALEN
- ZFNs
- Other Genome Editing Platforms
- Global Genome Editing Market, by Application
- Drug Development
- Plant Breeding
- Diagnostics
- Clinical Therapy
- Other Applications
- Global Genome Editing Market, by End User
- Biopharmaceutical Companies
- Agricultural Biotechnology
- Research Institutions
- Other End Users
- Geographic Breakdown
- Global Genome Editing Market, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Market Ranking Analysis
- Strategic Analysis
- Final Takeaways
Chapter 8 Sustainability in the Genome Editing Market: ESG Perspective
- Introduction to ESG
- Sustainability in Genome Editing: An ESG Perspective
- ESG Issues
- ESG Performance Analysis
- Environmental Performance
- Social Performance
- Governance Performance
- Concluding Remarks
List of Tables
Summary Table: Global Market for Genome Editing, by Technology, Through 2030
Table 1: CRISPR-based Therapies for Genetic Diseases
Table 2: Asia-Pacific Regulatory Landscape
Table 3: RoW Regulatory Landscape
Table 4: Clinical Trials in CRISPR Technology, by Type of Study
Table 5: Clinical Trials for CRISPR Technology, by Status, as of August 2024
Table 6: Clinical Trials for CRISPR Technology, by Phase, as of August 2024
Table 7: Clinical Trials, 2024
Table 8: Most CRISPR Technology Patents, by Applicant, 2020-2024
Table 9: Leading Patent Holders for CRISPR Technology, by Number of Patents, 2020-2024
Table 10: Genome Editing Technology Patents Filed, 2024 and 2025
Table 11: Global Market for Genome Editing, by Technology, Through 2030
Table 12: Global Market for CRISPR-Cas Genome Editing Technology, by Region, Through 2030
Table 13: Global Market for TALEN Genome Editing Technology, by Region, Through 2030
Table 14: Global Market for ZFN Genome Editing Technology, by Region, Through 2030
Table 15: Global Market for Other Genome Editing Technologies, by Region, Through 2030
Table 16: Global Market for Genome Editing, by Application, Through 2030
Table 17: Global Market for Genome Editing in Drug Development, by Region, Through 2030
Table 18: Global Market for Genome Editing in Plant Breeding, by Region, Through 2030
Table 19: Global Market for Genome Editing in Diagnostics, by Region, Through 2030
Table 20: Global Market for Genome Editing in Clinical Therapy, by Region, Through 2030
Table 21: Global Market for Genome Editing in Other Applications, by Region, Through 2030
Table 22: Global Market for Genome Editing, by End User, Through 2030
Table 23: Global Market for Genome Editing for Biopharmaceuticals, by Region, Through 2030
Table 24: Global Market for Genome Editing for Agricultural Biotechnology, by Region, Through 2030
Table 25: Global Market for Genome Editing for Research Institutions, by Region, Through 2030
Table 26: Global Market for Genome Editing for Other End Users, by Region, Through 2030
Table 27: Global Market for Genome Editing, by Region, Through 2030
Table 28: North American Market for Genome Editing, by Country, Through 2030
Table 29: North American Market for Genome Editing, by Technology, Through 2030
Table 30: North American Market for Genome Editing, by Application, Through 2030
Table 31: North American Market for Genome Editing, by End User, Through 2030
Table 32: European Market for Genome Editing, by Country, Through 2030
Table 33: European Market for Genome Editing, by Technology, Through 2030
Table 34: European Market for Genome Editing, by Application, Through 2030
Table 35: European Market for Genome Editing, by End User, Through 2030
Table 36: Asia-Pacific Market for Genome Editing, by Country, Through 2030
Table 37: Asia-Pacific Market for Genome Editing, by Technology, Through 2030
Table 38: Asia-Pacific Market for Genome Editing, by Application, Through 2030
Table 39: Asia-Pacific Market for Genome Editing, by End User, Through 2030
Table 40: RoW Market for Genome Editing, by Technology, Through 2030
Table 41: RoW Market for Genome Editing, by Application, Through 2030
Table 42: RoW Market for Genome Editing, by End User, Through 2030
Table 43: Ranking of Genome Editing Companies
Table 44: CRISPR Technology Companies
Table 45: Recent Developments in the CRISPR Technology Industry, 2022-2025
Table 46: Bioethical Issues and Risks Associated with CRISPR Technology
Table 47: ESG Rankings for Genome Editing Companies, 2024*
Table 48: ESG: Environmental Overview
Table 49: ESG: Social Overview
Table 50: ESG: Governance Overview
Table 51: Information Sources for this Report
Table 52: Abbreviations Used in this Report
Table 53: Agilent Technologies Inc.: Company Snapshot
Table 54: Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 55: Agilent Technologies Inc.: Product Portfolio
Table 56: Agilent Technologies Inc.: News/Key Developments, 2024
Table 57: Beam Therapeutics: Company Snapshot
Table 58: Beam Therapeutics: Financial Performance, FY 2023 and 2024
Table 59: Beam Therapeutics: Product Portfolio
Table 60: Beam Therapeutics: News/Key Developments, 2021-2023
Table 61: Caribou Biosciences Inc.: Company Snapshot
Table 62: Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 63: Caribou Biosciences Inc.: Product Portfolio
Table 64: Caribou Biosciences Inc.: News/Key Developments, 2021-2023
Table 65: Cellectis S.A.: Company Snapshot
Table 66: Cellectis S.A.: Financial Performance, FY 2023 and 2024
Table 67: Cellectis S.A.: Product Portfolio
Table 68: Cellectis S.A.: News/Key Developments, 2021-2024
Table 69: CRISPR Therapeutics: Company Snapshot
Table 70: CRISPR Therapeutics: Financial Performance, FY 2023 and 2024
Table 71: CRISPR Therapeutics: Product Portfolio
Table 72: CRISPR Therapeutics: News/Key Developments, 2021-2024
Table 73: Editas Medicine: Company Snapshot
Table 74: Editas Medicine: Financial Performance, FY 2023 and 2024
Table 75: Editas Medicine: Product Portfolio
Table 76: Editas Medicine: News/Key Developments, 2024 and 2025
Table 77: GenScript: Company Snapshot
Table 78: GenScript: Financial Performance, FY 2023 and 2024
Table 79: GenScript: Product Portfolio
Table 80: GenScript: News/Key Developments, 2022 and 2023
Table 81: Intellia Therapeutics Inc.: Company Snapshot
Table 82: Intellia Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 83: Intellia Therapeutics Inc.: Product Portfolio
Table 84: Merck KGaA: Company Snapshot
Table 85: Merck KGaA: Financial Performance, FY 2023 and 2024
Table 86: Merck KGaA: Product Portfolio
Table 87: Merck KGaA: News/Key Developments, 2021 and 2024
Table 88: Origene Technologies Inc.: Company Snapshot
Table 89: Origene Technologies Inc.: Product Portfolio
Table 90: Precision BioSciences: Company Snapshot
Table 91: Precision BioSciences: Financial Performance, FY 2023 and 2024
Table 92: Precision BioSciences: Product Portfolio
Table 93: Precision BioSciences: News/Key Developments, 2022 and 2025
Table 94: Sangamo Therapeutics: Company Snapshot
Table 95: Sangamo Therapeutics: Financial Performance, FY 2023 and 2024
Table 96: Sangamo Therapeutics: Product Portfolio
Table 97: Sangamo Therapeutics: News/Key Developments, 2024
Table 98: Takara Bio Inc.: Company Snapshot
Table 99: Takara Bio Inc.: Financial Performance, FY 2023 and 2024
Table 100: Takara Bio Inc.: Product Portfolio
Table 101: Takara Bio Inc.: News/Key Developments, 2024
Table 102: Thermo Fisher Scientific Inc.: Company Snapshot
Table 103: Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 104: Thermo Fisher Scientific Inc: Product Portfolio
Table 105: Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022
Table 106: Verve Therapeutics Inc.: Company Snapshot
Table 107: Verve Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 108: Verve Therapeutics Inc.: Product Portfolio
Table 109: Verve Therapeutics Inc.: News/Key Developments, 2024 and 2025
List of Figures
Summary Figure: Global Market Shares of Genome Editing, by Technology, 2024
Figure 1: Porter’s Five Forces Analysis for the Genome Editing Market
Figure 2: Market Dynamics Snapshot
Figure 3: Emerging Trends/Technologies in the CRISPR Market
Figure 4: Patents Granted Related to CRISPR Technology, by Year, 2020-2024
Figure 5: Global Market Shares of Genome Editing, by Technology, 2024
Figure 6: Workflow for CRISPR Gene Editing
Figure 7: Global Market Shares of Genome Editing, by Application, 2024
Figure 8: Global Market Shares of Genome Editing, by End User, 2024
Figure 9: Global Market Shares of Genome Editing, by Region, 2024
Figure 10: North American Market Shares of Genome Editing, by Country, 2024
Figure 11: European Market Shares of Genome Editing, by Country, 2024
Figure 12: Asia-Pacific Market Shares of Genome Editing, by Country, 2024
Figure 13: ESG Pillars
Figure 14: Advantages of ESG
Figure 15: Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 16: Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 17: GenScript: Revenue Shares, by Business Unit, FY 2024
Figure 18: GenScript: Revenue Shares, by Country/Region, FY 2024
Figure 19: Merck KGaA: Revenue Shares, by Business Unit, FY 2024
Figure 20: Merck KGaA: Revenue Shares, by Country/Region, FY 2024
Figure 21: Takara Bio Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 22: Takara Bio Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 23: Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 24: Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2024
